Home -> Law Blog Directory -> Federal Judiciary Blogs -> SCOTUSBLOG
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Federal Judiciary
: SCOTUSBLOGArgument preview: FDA drug labeling requirements and failure-to-warn claims
By Adam Schlossman
On March 30, in PLIVA, Inc. v. Mensing (consolidated with Actavis Elizabeth, L.L.C. v. Mensing), the Court will hear oral argument regarding whether a state can hold manufacturers liable for failing to include additional safety information that is not required by the FDA. Steven D. Schwinn, an associate professor of law at the John Marshall Law School and a co-editor of the Constitutional Law Prof Blog, previews the case for the American Bar Association?s PREVIEW of U.S. Supreme Court Cases; the ABA has generously agreed to share some of its previews ? which are authored by practitioners and scholars in the field ? with SCOTUSblog. You can read Professor Schwinn?s preview here; PREVIEW?s website is here.
Full post as published by SCOTUSBLOG on March 25, 2011 (boomark / email).
Pet Food Recall and Deaths
Dogs and Cats Sickened by Tainted Menu Food Products
Mitchell Report Summary
Report on Steroid Drug Use in Major League Baseball by Senator George Mitchell
Paxil Lawsuit
Paxil Claims, Lawsuits, and Injuries
Transdermal Drug Patches
Risk of Burns Missing From Some Labeling
Drug Manufacturer Rebates
Caremark Corp. agrees to pay $38.5 million settlement after convincing doctors to switch drug brands.
False Claims
Attorney Robert Arledge ordered to pay $5.8 million after making false Fen Phen settlement claims.
Georgette Klinger Spa
alleging unpaid wages and benefits and violation of the WARN Act.
Hardcore Energy Drinks
FDA, Health Canada Warn of Suspected Tampering
Wrinkle-Fillers
FDA to Review Labeling due to Adverse Event Reports

FDA Drug Regulation Preempts Failure-to-Warn Claim
5th Circuit Case Says No Preemption in Generic Reglan Lawsuit
Striking a Balance: Drug Labeling and the FDA
SCOTUS Holds that State Law Tort Actions are Not Preempted by FDCA







